- Conditions
- Healthy
- Interventions
- Exendin-9,39, Saline
- Biological · Other
- Lead sponsor
- Adrian Vella
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exendin 9,39, Placebo
- Drug
- Lead sponsor
- Adrian Vella
- Other
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Obesity, Type2diabetes, NAFLD
- Interventions
- Glucagon response study
- Drug
- Lead sponsor
- Adrian Vella
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Healthy
- Interventions
- Saline, Exendin-9,39
- Other · Biological
- Lead sponsor
- Adrian Vella
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Type2diabetes
- Interventions
- Caloric Restriction, Hyperglycemic clamp
- Behavioral · Drug
- Lead sponsor
- Adrian Vella
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Healthy
- Interventions
- 0.4mU Insulin followed by withdrawal period followed by 0.8mU study, 0.8mU Insulin followed by withdrawal period followed by 0.4mU study
- Drug
- Lead sponsor
- Adrian Vella
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Healthy, Type 2 Diabetes
- Interventions
- Saline, Exendin-9,39, Saline + Intralipid/Heparin, Exendin-9,39 + Intralipid/Heparin
- Biological
- Lead sponsor
- Adrian Vella
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exendin 9, 39, Placebo
- Drug
- Lead sponsor
- Adrian Vella
- Other
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1
- Interventions
- saline infusion, GLP-1-9,36 infusion, Exendin-9,39 at low dose, Exendin-9,39 at high dose
- Drug
- Lead sponsor
- Adrian Vella
- Other
- Eligibility
- 20 Years to 45 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota